This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Fennec Pharmaceuticals Q1 2026 Earnings
Business earnings call

Fennec Pharmaceuticals Q1 2026 Earnings

Analysis based on 6 articles · First reported May 07, 2026 · Last updated May 07, 2026

Sentiment
0
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement by Fennec Pharmaceuticals of its first quarter 2026 financial results and subsequent conference call provides transparency to investors, allowing them to assess the company's performance and future outlook. This event directly impacts Fennec Pharmaceuticals' stock price as investors react to the disclosed financial data and management's commentary.

Pharmaceuticals
Event Summary

Fennec Pharmaceuticals announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, before the opening of U.S. financial markets. Management will host a conference call and webcast on the same day at 8:30 a.m. Eastern Time to discuss the company's financial and business results. Fennec Pharmaceuticals is a specialty pharmaceutical company focused on commercializing PEDMARK to reduce ototoxicity in cancer patients. The company has an exclusive licensing agreement with Norgine for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand.

Entities Involved
stock
Fennec Pharmaceuticals
Fennec Pharmaceuticals announced it will release its first quarter 2026 financial results and host a conference call to discuss them.
Importance 100.0 Sentiment 0.0
priv
Norgine
Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.
Importance 20.0 Sentiment 0.0
per
Lindsay Rocco
Lindsay Rocco is a contact for corporate and media inquiries for Fennec Pharmaceuticals through Elixir Health Public Relations.
Importance 10.0 Sentiment 0.0
per
Robert Andrade
Robert Andrade is the Chief Financial Officer of Fennec Pharmaceuticals and a contact for investors.
Importance 10.0 Sentiment 0.0
priv
Elixir Health Public Relations
Elixir Health Public Relations is the public relations firm handling corporate and media inquiries for Fennec Pharmaceuticals.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.